The Clinical Effect of Bosingunyang-tang on Chronic Non-bacterial Prostatitis/Chronic Pelvic Pain Syndrome : Randomized Double-blind, Placebo-controlled Clinical Trial

  • Song, Moon-Koo (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Kang, Ji-Suck (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Kang, Cheol-Ho (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Ahn, Young-Min (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Ahn, Se-Young (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Doo, Ho-Kyung (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Lee, Byung-Cheol (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University)
  • Published : 2008.09.30

Abstract

Objective : Although chronic prostatitis/chronic pelvic pain syndrcme(CP/CPPS) is a common disease, there is no consensus on the etiology or pathology and treatment. This was a double-blinded, placebo-controlled, randomized clinical trial, investigating the therapeutic effects of the traditional Korean medicine, Bosingunyang-tang(BSGYT). Method : Participants who met US National Institutes of Health (NIH) consensus criteria for CP/CPPS were entered after applying inclusion/exclusion criteria. They were randomized to the BSGYT or placebo group. and treated three times a day for 6 weeks. NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) was used to estimate the clinical symptoms of CP/CPPS. Prostaglandin E2 and ${\beta}$-endorphin in prostatic fluid, collected by 2-glass pre-massage and post-massage test, were analyzed as factors associated with pain and inflammation. Result : The mean decrease in NIH-CPSI total score of the BSGYT group was 11.0 points, which is 5.7 points more than the placebo group. (Mann Whitney test P=0.038) Also the BSGYT group showed three times higher response rate than the placebo group in NIH-CPSI pain subscale score. (Fisher's exact test P=0.027) In those responders, prostaglandin E2 decreased significantly. (Wilcoxon's signed-ranks test P=0.037). No specific side effects were observed. Conclusion : After a 6-week treatment period, BSGYT improved clinical symptoms of CP/CPPS patients by decreasing PGE2 level in prostatic fluid.

Keywords